Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I inhibitor payload, and a drug‐to‐antibody ratio of ≈ 8. We have characterized the population pharmacokinetics (PK) of trastu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacol Ther
Egile Nagusiak: Yin, Ophelia, Xiong, Yuan, Endo, Seiko, Yoshihara, Kazutaka, Garimella, Tushar, AbuTarif, Malaz, Wada, Russ, LaCreta, Frank
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246728/
https://ncbi.nlm.nih.gov/pubmed/33118153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2096
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak